Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist. The single-dose portion of a Phase 1/2a trial enrolled 31 healthy adults without obesity. Six participants receiving 10 milligrams recorded a mean 3.3% body-weight reduction at day 24.
For investors, the attraction is measurable activity after one oral dose. The question is whether repeated treatment can sustain that response while keeping side effects manageable. The six-person result supports further development, with commercial value dependent on a usable long-term regimen.
BULL CASE
ACCG-2671’s approximately six-day half-life supports testing weekly dosing. If sustained efficacy and tolerability follow, an infrequently taken oral medicine could offer a meaningful convenience advantage.
Structure Therapeutics Inc. is now testing daily and weekly regimens in an 84-day, placebo-controlled multiple-dose study involving participants with obesity. A cohort receiving an injectable GLP-1 receptor agonist will also explore combination treatment. Results are expected in the first half of 2027.
That design addresses two potential sources of value: a standalone treatment and an additional option alongside GLP-1 therapy. A successful combination could broaden the program’s opportunity by demonstrating additional benefit for patients already receiving treatment.
The next readout can therefore do more than repeat an encouraging percentage. It can help identify a practical dosing schedule, assess whether gradual dose increases improve tolerability, and show whether weight continues declining during treatment.
BEAR CASE
The clearest concern is gastrointestinal tolerability. At 5 milligrams, four of five participants reported nausea and three reported vomiting. Gastrointestinal events affected all six participants at 10 milligrams. No serious adverse events were reported.
That puts tolerability at the center of the same cohort producing the headline weight-loss result. A regimen that produces substantial symptoms could undermine adherence, even if its weight effects are attractive. Slower dose escalation offers a development strategy, but its success must be demonstrated.
The study also provides limited evidence about treatment durability. Six healthy volunteers cannot establish efficacy across a broader population with obesity, and a single dose does not show how patients will respond over months. The reported 3.3% figure was not presented as a placebo-adjusted result.
A long half-life is commercially useful only if exposure remains manageable with repeat dosing. Investors should judge weight trajectories alongside adverse-event severity, discontinuations, and the doses participants can sustain.
Hedge Fund Sentiment
The filings available so far reflect positions held before Structure Therapeutics Inc. reported its ACCG-2671 Phase 1 results. Insider Monkey’s database showed 50 hedge funds holding Structure Therapeutics Inc. at the end of 2Q2026, down from 58 funds three months earlier.
CONCLUSION
Structure Therapeutics Inc. has an encouraging early signal but has yet to establish therapeutic efficacy. The investment case strengthens if repeat dosing produces sustained weight reduction with manageable gastrointestinal effects.
The next decisive evidence is a tolerable regimen that patients can maintain. The 2027 readout should carry more weight in assessing the program’s value than the initial six-person result.
READ NEXT: Vertiv (VRT) Signed a Deal Worth Up to $2.6B for UtilityInnovation. Can Faster Power Deployment Justify the Contingent Consideration? and Asana (ASAN) Reached a 10% Non-GAAP Operating Margin. Can Agentic Products Restore Expansion?
This article is originally published at Insider Monkey.
